The mAbs against PD-1 and its ligand PD-L1 (Atezolizumab, Avelumab and Durvalumab) are being used to treat a broad range of cancers, such as metastatic melanoma, renal-cell carcinoma (RCC), advanced non-small-cell lung cancer (NSCLC), Hodgkin’s lymphoma, bladder carcinoma, Merkel cell carcinoma, head and neck cancer, cutaneous squamous cell carcinoma (CSCC) and solid tumors [91, 92]. The gene discussed is CD274; the disease is renal cell carcinoma.